Prime Medicine, Inc.
PM359
Chronic Granulomatous Disease (CGD)
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews PM359 for Chronic Granulomatous Disease (CGD) around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 12h ago
“Prime Medicine continues to engage with the U.S. Food and Drug Administration (FDA) to explore ways to make PM359 available to patients with CGD. Based on recent interactions, Prime Medicine believes clinical data generated to-date may be s”